Bionovus Innovations

What Bionovus Innovations does

Bionovus Innovations is a private, Kansas City-based healthcare impact investing and venture firm founded in 2015 that invests in individuals and organizations advancing translational research from bench to bedside. Its core activity is structuring public-private partnerships — most notably with the University of Kansas Medical Center and its Institute for Advancing Medical Innovation (IAMI) — to convert academic discoveries into investable companies. The portfolio spans drug therapy (CicloMed, developing fosciclopirox for bladder cancer in Phase I/II trials), diagnostics (Smart Diagnostic Systems for food-borne pathogens; Alden for palm-sized microbe testing), animal health (ELIAS Animal Health, canine cancer immunotherapy), behavioral health services (Behavioral Health Holdings), medical devices (Cherry, customizable breast prosthetics), and health IT (Pathfinder, exited 2019).

The firm's operating model is relationship-driven rather than technology-platform driven. It does not develop proprietary consumer-facing technology; instead, it provides capital, industry expertise, and SBIR/STTR grant scaffolding through the CureBridge Collaborative, which organizes virtual biotech start-ups staffed by industry experts. Clinical research execution is delegated to CRO partners (Cmed Research, Clinipace, Notable Labs) and contract research providers such as MRIGlobal. Revenue mechanics are not publicly disclosed and the firm has reported only one realized exit (Pathfinder to CentralReach in 2019), so investor returns are tied to a small portfolio of translational assets rather than recurring fees or product sales.

Customer and geographic focus is highly concentrated in the Kansas City region's life-science ecosystem, with a stated mission to advance that community's capabilities. Leadership is led by President and CEO Tammy Ham, who also serves as CEO of portfolio company CicloMed and sits on the ELIAS Animal Health board, reinforcing the integrated portfolio management model.

Name

Bionovus Innovations

Legal name

BioNovus Innovations

Website

https://bionovus.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

Bionovus Innovations is a Kansas City-based healthcare impact investing firm, founded in 2015, that structures public-private partnerships and invests in translational research portfolio companies spanning drug therapy, diagnostics, animal health, and medical devices.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Healthcare venture capital
• Impact investing
• Translational research
• Biotech portfolio management
• Public-private partnerships

Headquarters

HQ city

Kansas City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Core offering

BioNovus Innovations is a healthcare-focused impact investing firm that creates public-private partnerships and invests capital in early-stage organizations advancing translational research. The firm manages a portfolio spanning drug development, medical devices, diagnostics, animal health, and health information technology, while connecting research institutions, industry expertise, and capital to move discoveries from bench to bedside.

Product overview

BioNovus Innovations is a healthcare-focused investment firm that has been creating public-private collaborations since 2015 to advance translational research from bench to bedside. The company's offering consists of investment in and support for a portfolio of portfolio companies spanning drug development (CicloMed with its fosciclopirox bladder cancer drug in Phase I/II trials), diagnostics (Smart Diagnostics for food-borne pathogens, Alden for handheld microbe testing), biotech startup organization (CureBridge Collaborative), animal health (ELIAS Animal Health for canine cancer immunotherapies), medical devices (Cherry for customizable breast prosthetics), and health IT (Pathfinder for ABA providers, exited in 2019). BioNovus does not develop or sell its own standalone product; rather, it enables the development and commercialization of healthcare innovations through strategic investments, partnerships with research institutions, and coordination with industry expertise. The company is headquartered at 4520 Main Street, Suite 1500, Kansas City, Missouri 64111.

Differentiator

Problem solved

Functional benefit

Products and services

• CicloMed Portfolio company developing fosciclopirox, a drug candidate for bladder cancer currently in Phase I/II clinical trials; BioNovus invested in and helped develop this University of Kansas spinoff.
• CureBridge Collaborative Public-private partnership with KU Medical Center and IAMI that organizes biotech companies staffed by industry experts and funded through SBIR and STTR grants for early-stage development and commercialization.
• Smart Diagnostics Systems Portfolio company developing assays to detect dangerous food-borne pathogens; invested in by BioNovus Innovations.
• ELIAS Animal Health Portfolio company advancing novel immunotherapies for canine cancers; invested in by BioNovus Innovations.
• Cherry Portfolio company offering fully-customizable breast prosthetics and size inclusive intimates; invested in by BioNovus Innovations.
• Pathfinder Software portfolio company serving ABA (Applied Behavior Analysis) providers; exited in 2019 through M&A acquisition.
• Alden Portfolio company developing breakthrough microbe testing technology in a palm-sized format; invested in by BioNovus Innovations.
• Behavioral Health Holdings Portfolio company delivering a full range of services for clients with autism; invested in by BioNovus Innovations.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Nine partnerships are on record, tiered core and minor.

• University of Kansas (KU) Medical CentercoreStrategic or Co-development PartnerBioNovus works closely with KU Medical Center engaging with faculty and practitioners to support research, training, and university-spinoff enterprises. This partnership includes the Institute for Advancing Medical Innovation (IAMI) and focuses on advancing health technologies and cancer drug development.
• Institute for Advancing Medical Innovation (IAMI)coreStrategic or Co-development PartnerIAMI is a key partner in the CureBridge Collaborative public-private partnership enabling early-stage development and commercialization by organizing biotech companies staffed by industry experts and funded through SBIR and STTR grants.
• Cmed ResearchminorStrategic or Co-development PartnerClinical research organization partnered with CicloMed to conduct studies related to fosciclopirox, the drug candidate for bladder cancer.
• ClinipaceminorStrategic or Co-development PartnerClinical research organization partnered with CicloMed to conduct studies related to fosciclopirox, the drug candidate for bladder cancer.
• Notable LabsminorStrategic or Co-development PartnerClinical research organization partnered with CicloMed to conduct studies related to fosciclopirox, the drug candidate for bladder cancer.
• MRIGlobalminorStrategic or Co-development PartnerInternationally recognized organization performing customized contract scientific and engineering research engaged for proof-of-concept and other studies.
• University of Kansas Cancer CentercoreStrategic or Co-development PartnerPartner institution for cancer research collaboration and clinical development initiatives in the Kansas City region.
• KU Edwards CampusminorStrategic or Co-development PartnerUniversity of Kansas partner supporting research, training, and university-spinoff enterprise development in the Kansas City region.
• CureBridge CollaborativecoreStrategic or Co-development PartnerPublic-private partnership organizing virtual biotech start-ups with KU Medical Center and IAMI, enabling early-stage development and commercialization.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cure Ventures: Early-stage life sciences venture firm focused on company creation in close collaboration with academic researchers and entrepreneurs. Comparable in translational research investment model and academic-anchored company formation approach.
• BioGenerator: St. Louis-based nonprofit life sciences venture builder that creates and invests in biotech startups sourced from regional research institutions. Directly comparable to BioNovus in mission, structure, and translational research thesis, with the same regional academic-anchor model.
• JumpStart Health: Cleveland-based healthcare-focused venture development organization (formerly BioEnterprise) that funds and supports health IT, medical device, and biotech startups. Directly comparable in translational research investment thesis and regional economic development focus.

Regional players

• Mid-America Angels: Kansas City-area angel investor network providing early-stage capital to Midwest companies. Comparable as a KC-region capital provider, though focused on smaller checks and broader sectors beyond healthcare.
• TechAccel: Kansas City-based venture and technology development firm investing in agriculture and animal health innovations. Comparable as a KC-region investor bridging research institutions and commercialization, with overlap in animal health portfolio exposure (ELIAS Animal Health).

Broad incumbents

• ARCH Venture Partners: Large, established life sciences venture firm investing in early-stage biotechnology companies sourced from top research institutions. Comparable as a translational research-focused investor, though operating at significantly larger scale and broader geographic scope.
• OrbiMed: Global healthcare-dedicated investment firm spanning biopharma, medical devices, and diagnostics across all stages. Comparable in healthcare-only mandate and translational biotech investing focus, though at much larger scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/bionovus-innovations

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionovus Innovations